Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523702 · ClinicalTrials.gov registry record · Phase 2
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03523702 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT03523702, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than standard treatment, which is a combination of chemotherapy and radiotherapy.
Interventions
- DRUG PembroRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523702
The ClinicalTrials.gov registry entry for NCT03523702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PembroRT is the first listed.
NCT03523702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523702 about?
NCT03523702 is a clinical study titled "The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial". The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than s...
What is the current status of trial NCT03523702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2018-08-30. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT03523702?
The interventions under investigation include: PembroRT (DRUG).
Who is sponsoring clinical trial NCT03523702?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.